Amyloid-β42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment

Journal of Alzheimer's Disease

Volumn 26, Issue 1, 2011, Pages 135-142

  Rolstad, Sindre ^a   Berg, Anne Ingeborg ^b   Bjerke, Maria ^a   Blennow, Kaj ^a   Johansson, Boo ^b   Zetterberg, Henrik ^a   Wallin, Anders ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Aging; cerebrospinal fluid; dementia; mild cognitive impairment; neuropsychology

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; AGING; ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE MODEL; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PRIORITY JOURNAL; SEMANTIC MEMORY; SEMANTICS; SENSORIMOTOR FUNCTION; VELOCITY; VISUOSPATIAL FUNCTION; VISUOSPATIAL MEMORY; WORKING MEMORY; CEREBROSPINAL FLUID; MENTAL HEALTH; MIDDLE AGED; PHYSIOLOGY; REGRESSION ANALYSIS; SHORT TERM MEMORY; VISION;

AGED; AMYLOID BETA-PEPTIDES; COGNITION; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; MENTAL STATUS SCHEDULE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS; TAU PROTEINS; VISUAL PERCEPTION;

EID: 80052868367     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110038     Document Type: Article

References (36)

1. Blennow K (2004) CSF biomarkers for mild cognitive impairment. J Intern Med 256, 224-234. (Pubitemid 39222991)
2. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519. (Pubitemid 43358072)
3. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.JAMA302, 385-393.
4. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246. (Pubitemid 39222993)
5. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613. (Pubitemid 37162569)
6. Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K (2001) Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379. (Pubitemid 32217453)
7. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cere-brospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
8. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E (2010) Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry 25, 403-410.
9. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537.
10. van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM (2009) CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 72, 1056-1061.
11. Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, Scheltens PH (2005) Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 11, 8-13. (Pubitemid 40372855)
12. Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A (2008) Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities inMCI. J Int Neuropsy-chol Soc 14, 582-590. (Pubitemid 351935880)
13. Samuels SC, Silverman JM, Marin DB, Peskind ER, Younki SG, Greenberg DA, Schnur E, Santoro J, Davis KL (1999) CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 52, 547-551. (Pubitemid 29075601)
14. Engelborghs S, Maertens K, Vloeberghs E, Aerts T, Somers N, Marien P, De Deyn PP (2006) Neuropsychological and behavioural correlates of CSF biomarkers in dementia. Neurochem Int 48, 286-295. (Pubitemid 43177150)
15. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
16. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A (2005) The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 76, 1485-1490. (Pubitemid 41531690)
17. Reisberg B, Ferris SH, de Leon MJ, Crook T (1988) Global Deterioration Scale (GDS).Psychopharmacol Bull 24, 661-663.
18. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M (1996) Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 9, 185-199. (Pubitemid 27028870)
19. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
20. Royall DR, Mahurin RK, Gray KF (1992) Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 40, 1221-1226.
21. Morris JC (1997) Clinical dementia rating: areliable and valid diagnostic and staging measure for dementiaof the Alzheimer type. Int Psychogeriatr 9 Suppl 1, 173-176; discussion 177-178. (Pubitemid 28045357)
22. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, Syversen S, Mattsson UB, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A (2007) Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 12, 255-260. (Pubitemid 350179256)
23. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 26, 231-245. (Pubitemid 26002016)
24. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680. (Pubitemid 29266465)
25. Simes RJ (1986) An improved Bonferroni procedure for multiple tests of significance. Biometrika, 751-754.
26. Nordlund A, Rolstad S, Klang O, Lind K, Hansen S, Wallin A (2007) Cognitive profiles of mild cognitive impairment with and without vascular disease. Neuropsychology 21, 706-712. (Pubitemid 350116514)
27. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stageAlzheimerdisease.Arch Neurol58, 397-405. (Pubitemid 32217456)
28. Nordlund A, Rolstad S, Klang O, Edman A, Hansen S, Wallin A (2010) Two year outcome of MCI subtypes and aetiologies in the Goteborg MCI study. J Neurol Neurosurg Psychiatry 81, 541-546.
29. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K (2003) Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord 15, 169-176. (Pubitemid 36206647)
30. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67, 217-223.
31. Rolstad S, Nordlund A, Eckerström, Gustavsson MH, Zetterberg H, Wallin A (2009) Cognitive Reserve in Relation to Abeta42 in Patients Converting from MCI to Dementia-A Follow-Up Report. Dement Geriatr Cogn Disord 28, 110-115.
32. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Blennow K, Olesen PJ, Zetterberg H, Wallin A (2010) High education may offer protection against tauopathy in patients with mild cognitive impairment. J Alzheimers Dis 21, 221-228.
33. Rolstad S, Nordlund A, Eckerstrom C, Gustavsson MH, Zetterberg H, Wallin A (2009) Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment-proof of concept. Dement Geriatr Cogn Disord 27, 194-200.
34. Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman HH, Hsiung GY, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, George-Hyslop PS, Wherrett J, Monsch AU (2010) An exploration of cognitive subgroups in Alzheimer's disease. J Int Neuropsychol Soc 16, 233-243.
35. Chetelat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC (2010) Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133, 3349-3358.
36. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12, 383-388.